Conditions: ADHD
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 129
Healthy volunteers: no

Brief summary:
The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M. Flynn and Pelham (SKAMP) deportment scale in children (aged 6-12) diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Vyvanse (lisdexamfetamine dimesylate) intervention 2: Placebo
Intervention descriptions: intervention 1: Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day). intervention 2: Placebo

Protocol document: